Mindray (MR) off as much as 15% today on a downgrade from Credit Suisse. But I missed it at $18 and will sit and watch. The news is not encouraging (March orders weaker than Jan and Feb...ouch!) and I am not a great bull on China right now. I also missed China Med (CMED) below $14 (had a big run-up over $20), but I've got no interest in chasing and am very cautious on CMED (smoke surrounds that company). MR seems like the higher quality play.
Disclaimer: No position in these stocks either personally or professionally.
No comments:
Post a Comment